B/F/TAF is named as a drug or biological intervention in 8 clinical trials in our USA, UK and China trial registers, 3 of which are recruiting. Lead sponsors include Gilead Sciences (7) and Affiliated Hospital of Nantong University (1). Registered phases: Phase 3, Phase 2/3, Phase 2, Phase 1 and Observational. Conditions studied include HIV-1-infection; HIV-1 Infection; HIV Infection.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| HIV-1-infection | 5 |
| HIV-1 Infection | 2 |
| HIV Infection | 1 |
| Lead sponsor | Trials |
|---|---|
| Gilead Sciences | 7 |
| Affiliated Hospital of Nantong University | 1 |
| Register | B/F/TAF trials |
|---|---|
| Clinical trials in USA | 7 |
| Clinical trials in UK | 2 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how B/F/TAF works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists B/F/TAF (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.